A clinical utility evaluation of dual HIV/Syphilis point-of-care tests in non-clinical settings for screening for HIV and syphilis in men who have sex with men.
Diagnostic evaluation
HIV
Men who have Sex with Men
Non-Governmental Organizations
Point-of-care
Public health
STI testing
Syphilis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
15
09
2022
accepted:
11
01
2024
medline:
1
3
2024
pubmed:
29
2
2024
entrez:
28
2
2024
Statut:
epublish
Résumé
Dual point-of-care tests (POCTs) for the simultaneous detection of antibodies to HIV and syphilis have been developed. Since community-based organisations (CBO) are effective providers of HIV and syphilis testing among men who have sex with men (MSM), evaluation of the utility of these dual tests at CBO testing services is a high priority. The aim of this study is to determine the feasibility of performing dual HIV-syphilis POCT testing among both users and providers at these non-clinical sites. This evaluation assessed the utility of two lateral flow immunochromatographic antibody technologies for dual screening for HIV/syphilis among MSM seeking testing in four CBO testing services in Spain, Slovenia, Latvia, and Ukraine. The study's conceptual framework divides the concept of feasibility into two inter-related domains, acceptability, and usability and further breaks it down into six subdomains: learnability, willingness, suitability, satisfaction, efficacy, and effectiveness. The feasibility analysis was performed by calculating the median score in 3 stages (for individual questions, subdomains, and domains), using a summated scores method. The final sample included 844 participants, 60 of which were found to be HIV test positive (7.1%) and 61 (7.2%) positive on testing for syphilis. There was a small difference (1.1%) when comparing the results of the two dual POCTs under evaluation to the tests routinely used at each site. The inter-rater agreement showed a high concordance between two independent readings. The analysis of the feasibility for the users of the services indicated good satisfaction, suitability, and willingness. In addition, among 18 providers the total mean score showed good acceptability and usability, good willingness, easy learnability, high suitability, and good efficacy, but lower satisfaction and effectiveness. The operational characteristics of both dual study POCTs were well evaluated by providers. The introduction of dual HIV and syphilis POCTs in CBO testing services for screening of MSM is feasible, with a high acceptability and usability both for users and providers. Implementation of dual POCTs for HIV and syphilis in CBO testing services is an opportunity for scaling up integrated HIV/syphilis testing for MSM.
Sections du résumé
BACKGROUND
BACKGROUND
Dual point-of-care tests (POCTs) for the simultaneous detection of antibodies to HIV and syphilis have been developed. Since community-based organisations (CBO) are effective providers of HIV and syphilis testing among men who have sex with men (MSM), evaluation of the utility of these dual tests at CBO testing services is a high priority. The aim of this study is to determine the feasibility of performing dual HIV-syphilis POCT testing among both users and providers at these non-clinical sites.
METHODS
METHODS
This evaluation assessed the utility of two lateral flow immunochromatographic antibody technologies for dual screening for HIV/syphilis among MSM seeking testing in four CBO testing services in Spain, Slovenia, Latvia, and Ukraine. The study's conceptual framework divides the concept of feasibility into two inter-related domains, acceptability, and usability and further breaks it down into six subdomains: learnability, willingness, suitability, satisfaction, efficacy, and effectiveness. The feasibility analysis was performed by calculating the median score in 3 stages (for individual questions, subdomains, and domains), using a summated scores method.
RESULTS
RESULTS
The final sample included 844 participants, 60 of which were found to be HIV test positive (7.1%) and 61 (7.2%) positive on testing for syphilis. There was a small difference (1.1%) when comparing the results of the two dual POCTs under evaluation to the tests routinely used at each site. The inter-rater agreement showed a high concordance between two independent readings. The analysis of the feasibility for the users of the services indicated good satisfaction, suitability, and willingness. In addition, among 18 providers the total mean score showed good acceptability and usability, good willingness, easy learnability, high suitability, and good efficacy, but lower satisfaction and effectiveness. The operational characteristics of both dual study POCTs were well evaluated by providers.
CONCLUSIONS
CONCLUSIONS
The introduction of dual HIV and syphilis POCTs in CBO testing services for screening of MSM is feasible, with a high acceptability and usability both for users and providers. Implementation of dual POCTs for HIV and syphilis in CBO testing services is an opportunity for scaling up integrated HIV/syphilis testing for MSM.
Identifiants
pubmed: 38419023
doi: 10.1186/s12879-024-09017-5
pii: 10.1186/s12879-024-09017-5
pmc: PMC10902924
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
264Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2024. The Author(s).
Références
BMJ Open. 2022 Aug 11;12(8):e056887
pubmed: 35953255
PLoS Med. 2013 Aug;10(8):e1001496
pubmed: 23966838
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S187-99
pubmed: 23764635
Int J STD AIDS. 2021 May;32(6):501-509
pubmed: 33533303
AIDS Res Treat. 2013;2013:819593
pubmed: 24527210
BMJ Open. 2014 Dec 15;4(12):e006859
pubmed: 25510889
Sex Transm Infect. 2017 Dec;93(S4):S51-S58
pubmed: 29223963
PLoS One. 2018 Jul 10;13(7):e0198698
pubmed: 29990336
BMC Infect Dis. 2024 Feb 29;24(Suppl 1):194
pubmed: 38418989
Sex Transm Infect. 2017 Dec;93(S4):S81-S88
pubmed: 29223966
Implement Sci. 2012 Jan 23;7:5
pubmed: 22269037
BMJ Open. 2022 Jun 8;12(6):e055275
pubmed: 35676020
Sex Transm Infect. 2020 Aug;96(5):342-347
pubmed: 32241905
J Grad Med Educ. 2013 Dec;5(4):541-2
pubmed: 24454995
Rev Panam Salud Publica. 2016 Dec;40(6):455-461
pubmed: 28718495
Sex Transm Infect. 2017 Dec;93(S4):S3-S15
pubmed: 28747410
J Int AIDS Soc. 2017 Jun 28;20(1):21579
pubmed: 28691435